 |
Journal articles
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.
Franck Morschhauser
1, *
Christian Recher
2
Noël Milpied
3
Remy Gressin
4
Gilles Salles
5
Pauline Brice
6
Norbert Vey
7
Corinne Haioun
8
Philippe Colombat
9
Jean-François Rossi
10
Eric Deconinck
11
F. Lazreg
12
Loïc Bergougnoux
12
Georges Delsol
2
Michel Attal
2, 13
*
Corresponding author
Franck Morschhauser 1
Correspondent author
Christian Recher 2
Author
Noël Milpied 3
Author
Remy Gressin 4
Author
Philippe Colombat 9
Author
Jean-François Rossi 10
Author
Eric Deconinck 11
Author
F. Lazreg 12
Author
1
Service d'hématologie (Lille - France)
- Hôpital Claude Huriez [Lille] (rue Michel Polonowski,
59000 Lille - France)
- CHU Lille (2 avenue Oscar Lambret 59000 Lille - France)
- CHRU Lille - Centre Hospitalier Régional Universitaire [Lille] (2, avenue Oscar Lambret - 59037 Lille Cedex - France)
2
Service d'hématologie (Toulouse - France)
- CHU Toulouse [Toulouse] (Hôtel-Dieu Saint Jacques 2, rue Viguerie TSA 80035 31059 Toulouse cedex 9 - France)
- Hôpital Purpan [Toulouse] (Place du Docteur Baylac
TSA 40031
31059 Toulouse cedex 9 - France)
- CHU Toulouse [Toulouse] (Hôtel-Dieu Saint Jacques 2, rue Viguerie TSA 80035 31059 Toulouse cedex 9 - France)
3
Service d'hématologie (France)
- CHU Bordeaux [Bordeaux] (place Amélie Raba Léon 33076 BORDEAUX CEDEX - France)
4
Service d'hématologie (Grenoble - France)
- CHU Grenoble (France)
- Hôpital Michallon (CHU Grenoble-Alpes - France)
5
Service d'hématologie/oncologie (Lyon - France)
- CHU Lyon (France)
- CHLS - Centre Hospitalier Lyon Sud [CHU - HCL] (165 Chemin du Grand Revoyet
69495 Pierre-Bénite - France)
- HCL - Hospices Civils de Lyon (3 Quai des Célestins 69002 Lyon - France)
6
Service d'hématologie-oncologie adultes (1, avenue Claude-Vellefaux 75475 PARIS Cedex 10 - France)
- AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) (France)
- UPD7 - Université Paris Diderot - Paris 7 (5 rue Thomas-Mann - 75205 Paris cedex 13 - France)
- Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris] (200 rue du Faubourg Saint-Denis 75475 Paris (Nord) Cedex 10 - France)
7
Service d'Hématologie (Marseille - France)
8
Service d'hématologie clinique (Créteil - France)
- AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) (France)
- Hôpital Henri Mondor (France)
- UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12 (61 avenue du Général de Gaulle - 94010 Créteil cedex - France)
9
Service d'hématologie [Tours] (France)
10
Service d'hématologie et oncologie médicale (34000 Montpellier - France)
- UM1 - Université Montpellier 1 (5, boulevard Henri IV - CS 19044 - 34967 Montpellier cedex - France)
- CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier] (191 avenue du doyen Gaston Giraud 34295 Montpellier cedex 5 - France)
- Hôpital Lapeyronie (France)
- UM - Université de Montpellier (163 rue Auguste Broussonnet - 34090 Montpellier - France)
11
Service d'hématologie (France)
13
Laboratoire d'Hématologie [Purpan] (Pôle Biologie, Place du Docteur Baylac - TSA 40031 - 31059 Toulouse cedex 9 - France)
- UT3 - Université Toulouse III - Paul Sabatier (118 route de Narbonne - 31062 Toulouse - France)
- Université Fédérale Toulouse Midi-Pyrénées (41 Allée Jules Guesde, 31000 Toulouse - France)
- CHU Toulouse [Toulouse] (Hôtel-Dieu Saint Jacques 2, rue Viguerie TSA 80035 31059 Toulouse cedex 9 - France)
- Hôpital Purpan [Toulouse] (Place du Docteur Baylac
TSA 40031
31059 Toulouse cedex 9 - France)
- CHU Toulouse [Toulouse] (Hôtel-Dieu Saint Jacques 2, rue Viguerie TSA 80035 31059 Toulouse cedex 9 - France)
Abstract : BACKGROUND: This study explored the efficacy and safety of rituximab as treatment of clinical or molecular residual disease after autologous stem-cell transplantation (ASCT) in follicular lymphoma (FL). PATIENTS AND METHODS: Forty patients with CD20+ FL and clinically (group A, n = 14) or clono-specific PCR-detectable (group B, n = 25) residual disease persisting 3 months after ASCT received rituximab 375 mg/m² once weekly for 4 weeks. RESULTS: Response rate at day 50 was 36% [90% confidence interval (CI) 15-61] in group A (World Health Organization criteria) and 52% (90% CI 34-70) in group B (conversion PCR-undetectable status to undetectable status). The best response rate was 71% [nine complete responses (CRs) and one partial response] in group A and 76% in group B. At 36 months, all 10 responses persisted in group A, whereas 46% of patients in group B still had PCR-undetectable disease. Furthermore, 68% of patients in group B were still in clinical CR. Rituximab after ASCT was safe with few grade 3-4 toxic effects (15% patients), mainly acute reactions and infections. CONCLUSION: Rituximab induced a high rate of durable CRs in patients with clinically detectable disease, as well as durable eradication of PCR-detectable disease in patients with FL after ASCT. Continued molecular responses assessed with a highly sensitive and clono-specific PCR technique were correlated with an excellent disease control.
Document type :
Journal articles
Domain :
Complete list of metadata
https://www.hal.inserm.fr/inserm-00862711
Contributor : Philippe Saas Connect in order to contact the contributor
Submitted on : Tuesday, September 17, 2013 - 1:06:40 PM
Last modification on : Tuesday, October 19, 2021 - 4:08:17 PM
Contributor : Philippe Saas Connect in order to contact the contributor
Submitted on : Tuesday, September 17, 2013 - 1:06:40 PM
Last modification on : Tuesday, October 19, 2021 - 4:08:17 PM
Links full text
Identifiers
- HAL Id : inserm-00862711, version 1
- DOI : 10.1093/annonc/mds202
- PUBMED : 22767588
Collections
INSERM | UNIV-PARIS7 | UPEC-UPEM | USPC | HCL | CHLS | UNIV-MONTPELLIER | UNIV-TLSE3 | UPEC | UNIV-PARIS
Citation
Franck Morschhauser, Christian Recher, Noël Milpied, Remy Gressin, Gilles Salles, et al.. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.. Annals of Oncology, Elsevier, 2012, 23 (10), pp.2687-95. ⟨10.1093/annonc/mds202⟩. ⟨inserm-00862711⟩
Metrics
Record views